When I approach consideration of treatment, it is clear that TP53 mutation or del(17)(p13)  chromosome region on interphase cytogenetics identifies a group of patients at risk for progression after treatment with a venetoclax containing regimen and also to a lesser extent BTKi (ibrutinib/acalab...